About 818 results

ALLMedicine™ Guillain-barre Syndrome Center

Research & Reviews  258 results

Variant Guillain-Barre Syndrome Following SARS-CoV-2 Vaccination: Case Report and Revie...
The Canadian Journal of Neurological Sciences. Le Journal... Donaldson L, Margolin E

May 10th, 2022 - Variant Guillain-Barre Syndrome Following SARS-CoV-2 Vaccination: Case Report and Review of the Literature.|2022|Donaldson L,Margolin E,|

Guillain-Barré Syndrome Related and Unrelated to COVID-19: Clinical Follow-Up in the CO...
Physical Therapy; Masuccio FG, Tipa V et. al.

May 6th, 2022 - COVID-19 has been associated with neurological complications such as Guillain-Barre syndrome (GBS). Several cases have been reported, but without functional outcome data after intensive rehabilitation and medium-term follow-up. In this observation...

Outcomes of patients presenting with Guillain-Barre Syndrome at a tertiary care center ...
BMC Neurology; Patel P, Shah D et. al.

Apr 24th, 2022 - The Guillain-Barre Syndrome (GBS), also known as acute idiopathic polyneuritis, is a critical acquired condition associated with preceding nonspecific infection or triggering factors like trauma, surgery, or vaccination. GBS is currently the most ...

The legacy of ZikaPLAN: a transnational research consortium addressing Zika.
Global Health Action; Wilder-Smith A, Brickley EB et. al.

Apr 5th, 2022 - Global health research partnerships with institutions from high-income countries and low- and middle-income countries are one of the European Commission's flagship programmes. Here, we report on the ZikaPLAN research consortium funded by the Europ...

Assessment of Guillain-Barre Syndrome Cases in Brazil in the COVID-19 Era.
The Neurologist; Aquino Ferraz LD, Marques NP et. al.

Mar 30th, 2022 - Assessment of Guillain-Barre Syndrome Cases in Brazil in the COVID-19 Era.|2022|Aquino Ferraz LD,Marques NP,Silveira DMM,de Magalhães MJS,Oliveira EA,|epidemiology,diagnosis,epidemiology,

see more →

Drugs  6 results see all →

Clinicaltrials.gov  4 results

Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome

Mar 16th, 2022 - Guillain-Barre syndrome (GBS) is an immune-mediated acute inflammatory peripheral neuropathy. The currently proven effective treatment methods include intravenous immunoglobulin and plasma exchange. In the clinical treatment process, the plasma so...

Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome

Apr 7th, 2015 - PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to receive either human immunoglobulin infusion (IVIg) (arm I) or plasmapheresis (arm II). Arm I patients receive liquid heat-treated IVIg for 4 days starting on da...

Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study

Sep 23rd, 2014 - Guillian-Barre Syndrome (GBS) is the most frequent cause of acute neuromuscular weakness in the Western World and can occur at any age. GBS is a rpadily progressive 'inflammatory' disorder of the perihperal nerves often leading to sever paresis of...

Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological...

Jan 31st, 2012 - This research looks for markers in the blood of people with spinal cord injury that may be a sign of injury severity, or serve as a clue to the degree of recovery. Investigators would also like to compare the marker profile of these patient with t...

see more →

News  48 results

 Muscle-wasting Conditions May be More Common in the UK Than Previous Estimates

Feb 16th, 2022 - Tens of thousands more people in the UK could be living with neuromuscular disease (NMD) than previous estimates suggested, according to new research. A study in the journal PLOS ONE, which analysed millions of GP records, suggested that the preva...

Slight Increase in Risk of Guillain-Barre After Recombinant Zoster Vaccine Confirmed

Nov 2nd, 2021 - NEW YORK (Reuters Health) - An analysis of Medicare claims data found an increased risk of Guillain-Barre syndrome (GBS) following receipt of the recombinant zoster vaccine (RZV), confirming the same "signal" from the U.S. Centers for Disease Cont...

Safety Signal for Guillain-Barre With J&J COVID-19 Shot Confirmed in Surveillance Data

Oct 14th, 2021 - NEW YORK (Reuters Health) - Data from the vaccine adverse event reporting system (VAERS) show a potential "small but statistically significant safety concern" for the development of Guillain-Barre syndrome (GBS) after receipt of the Janssen/Johnso...

The Delta Factor
Cynthia Geppert, MD, MA, MPH, MSBE

Sep 13th, 2021 - Several weeks ago, I received a call from my brother who, though not a health care professional, wanted me to know he thought the public was being too critical of scientists and physicians who “are giving us the best advice they can about COVID. P.

EU Lists Rare Nerve Disorder as Side Effect of J&J COVID-19 Vaccine

Jul 23rd, 2021 - (Reuters) - Europe's medicines regulator said on Thursday it had added a nerve-degenerating disorder, Guillain-Barré syndrome, as a possible rare side effect from Johnson & Johnson's COVID-19 vaccine after it reviewed 108 cases reported worldwide....

see more →

Patient Education  11 results see all →